BioXcel Therapeutics Inc (NASDAQ: BTAI)’s stock price has increased by 73.61 compared to its previous closing price of 2.16. However, the company has seen a 90.36% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-03 that NEW HAVEN, Conn., March 03, 2025 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale in a registered direct offering of 4,000,000 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”) (or common stock equivalents in lieu thereof), and accompanying warrants (the “Accompanying Warrants”) to purchase up to 4,000,000 shares of Common Stock at a combined offering price of $3.50 per Share (or per common stock equivalent in lieu thereof) and Accompanying Warrant, for aggregate gross proceeds to the Company of approximately $14 million before deducting the placement agent’s fees and other estimated offering expenses payable by the Company (excluding the proceeds, if any, from the exercise of the Accompanying Warrants). The Accompanying Warrants have an exercise price of $4.20 per share of Common Stock, are exercisable at any time after the date of issuance, subject to certain ownership limitations, and expire five years from the date of issuance. The Company has also granted the purchasers the option, exercisable at any time and from time to time, for two weeks after the closing of this offering to purchase up to an additional 4,000,000 Shares (or common stock equivalents in lieu thereof) and Accompanying Warrants to purchase an additional 4,000,000 shares of Common Stock from the Company, at a combined offering price of $3.50 per Share (or per common stock equivalent in leu thereof) and Accompanying Warrant.
Is It Worth Investing in BioXcel Therapeutics Inc (NASDAQ: BTAI) Right Now?
Additionally, the 36-month beta value for BTAI is 0.90. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for BTAI is 2.58M and currently, short sellers hold a 11.03% ratio of that float. The average trading volume of BTAI on March 04, 2025 was 1.83M shares.
BTAI’s Market Performance
BTAI stock saw a decrease of 90.36% in the past week, with a monthly decline of -27.42% and a quarterly a decrease of -49.47%. The volatility ratio for the week is 55.37%, and the volatility levels for the last 30 days are 24.60% for BioXcel Therapeutics Inc (BTAI). The simple moving average for the last 20 days is 35.84% for BTAI stock, with a simple moving average of -68.65% for the last 200 days.
Analysts’ Opinion of BTAI
Many brokerage firms have already submitted their reports for BTAI stocks, with UBS repeating the rating for BTAI by listing it as a “Neutral.” The predicted price for BTAI in the upcoming period, according to UBS is $4 based on the research report published on February 21, 2024 of the previous year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see BTAI reach a price target of $4, previously predicting the price at $40. The rating they have provided for BTAI stocks is “Neutral” according to the report published on August 15th, 2023.
BTAI Trading at -19.60% from the 50-Day Moving Average
After a stumble in the market that brought BTAI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.11% of loss for the given period.
Volatility was left at 24.60%, however, over the last 30 days, the volatility rate increased by 55.37%, as shares sank -28.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.33% lower at present.
During the last 5 trading sessions, BTAI rose by +90.36%, which changed the moving average for the period of 200-days by -89.27% in comparison to the 20-day moving average, which settled at $2.76. In addition, BioXcel Therapeutics Inc saw -37.32% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BTAI starting from O’Neill Vincent, who sale 165 shares at the price of $0.35 back on Dec 16 ’24. After this action, O’Neill Vincent now owns 19,957 shares of BioXcel Therapeutics Inc, valued at $58 using the latest closing price.
Mehta Vimal, the CEO and President of BioXcel Therapeutics Inc, sale 3,117 shares at $0.36 during a trade that took place back on Dec 16 ’24, which means that Mehta Vimal is holding 59,605 shares at $1,131 based on the most recent closing price.
Stock Fundamentals for BTAI
Current profitability levels for the company are sitting at:
- -32.96 for the present operating margin
- 0.04 for the gross margin
The net margin for BioXcel Therapeutics Inc stands at -31.19. The total capital return value is set at -3.21. Equity return is now at value -1766.94, with -95.08 for asset returns.
Based on BioXcel Therapeutics Inc (BTAI), the company’s capital structure generated 5.43 points at debt to capital in total, while cash flow to debt ratio is standing at -0.8. The debt to equity ratio resting at -1.23. The interest coverage ratio of the stock is -5.16.
Currently, EBITDA for the company is -165.42 million with net debt to EBITDA at -1.15. When we switch over and look at the enterprise to sales, we see a ratio of 33.49. The receivables turnover for the company is 758.67for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.87.
Conclusion
In conclusion, BioXcel Therapeutics Inc (BTAI) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
